New hope for Tough-to-Treat blood cancer? early trial tests novel drug mix
NCT ID NCT01562405
Summary
This is an early-stage study to find the safest, highest dose of a new injectable drug (sotatercept) when combined with two existing oral medications for multiple myeloma. It involves 33 adults whose cancer has returned or stopped responding to prior therapy. The main goal is to see how well patients tolerate the combination, while also gathering initial information on whether it helps control the cancer and related bone and blood cell problems.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02215, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Emory University
Atlanta, Georgia, 30322, United States
-
Massachusetts General Hosptial
Boston, Massachusetts, 02115, United States
Conditions
Explore the condition pages connected to this study.